Colorectal cancer (CRC) impacts the colon and rectum, ranking as the fourth deadliest cancer worldwide, accounting for 10% of cancer cases and 9.4% of cancer-related deaths. CRC is frequently without symptoms until it reaches its later stages. Screening programs, including colonoscopies and tests on stool samples, have enhanced the chances of survival for people younger than fifty. The TNM staging system, which evaluates tumor size, lymph node involvement, and metastasis, is commonly utilized. Factors that increase the risk of developing colorectal cancer include exposure to chemicals, chronic inflammatory bowel disease, obesity, smoking, family history, genetic mutations, and specific diets. Diets high in fat, consumption of too much iron, sugary beverages, and meals with high sugar content can elevate the risk of CRC, whereas incorporating whole grains, fiber, calcium, vitamin D, dairy products, vegetables, fruits, and green tea into your diet can lower the risk. Management differs depending on stage: stages 0 and I are treated with endoscopy and local excision, whereas stages II, III, and IV necessitate systemic treatments like immunotherapy, targeted therapy, and chemotherapy.

Catalpol, classified as an iridoid glucoside, is recognized for its significant role in medicine, particularly in the treatment of various conditions such as diabetes mellitus, neuronal disorders, and inflammatory diseases. This review aims to evaluate the biological implications of catalpol and the mechanisms underlying its diverse pharmacological effects. A thorough exploration of existing literature was conducted utilizing the keyword "Catalpol" across prominent public domains like Google Scholar, PubMed, and EKB. Catalpol has demonstrated a diverse array of pharmacological effects in experimental models, showcasing its anti-diabetic, cardiovascular-protective, neuroprotective, anticancer, hepatoprotective, anti-inflammatory, and antioxidant properties. In summary, catalpol manifests a spectrum of biological effects through a myriad of mechanisms, prominently featuring its anti-inflammatory and antioxidant capabilities. Its diverse pharmacological profile underscores its potential for therapeutic applications across a range of conditions. Further research is warranted to fully elucidate the clinical implications of catalpol and optimize its use in medical practice.

Zinc plays an important role in glucose metabolism and lipid regulation, and its imbalance has been implicated in the development of type 2 diabetes, metabolic syndrome, and dyslipidemia. A case–control study was conducted on 100 patients with type 2 diabetes and 95 controls. Serum zinc levels, metabolic panel and Blood pressure, were measured. Demographic and treatment-related factors were assessed to evaluate their potential influence on trace element status. Moreover, dietary zinc consumption was estimated. Diabetic patients had significantly lower serum zinc levels compared to non-diabetic participants despite comparable intake. In addition, each unit (mcg/dL) increase in serum zinc was associated with 10% lower odds of diabetes prevalence (p = 0.003). Total TC, TG, and LDL were all significantly increased in patients with diabetes (p < 0.001), each 1 mg/dL increase in LDL-cholesterol increased the odds of zinc deficiency by 4% (p = 0.03). Individuals with diabetes had significantly lower diastolic blood pressure as compared to healthy participants (p = 0.01). People with diabetes display different blood pressure and lipid patterns, as well as lower serum zinc concentrations, despite having dietary zinc intake comparable to those without diabetes. Higher serum zinc levels are associated with reduced odds of having diabetes. However, because these findings are based on cross-sectional data, further longitudinal and intervention studies are needed to determine the most effective zinc formulations and dosing regimens.